$RKDA
Arcadia Biosciences, Inc.

2016 Q3 Form 10-Q Financial Statement

#000156459016028976 Filed on November 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2015 Q4
Revenue $102.0K $1.350M
YoY Change -94.4% -51.79%
Cost Of Revenue $60.00K $670.0K
YoY Change -1.64% 857.14%
Gross Profit $42.00K $680.0K
YoY Change -97.62% -75.09%
Gross Profit Margin 41.18% 50.37%
Selling, General & Admin $2.687M $2.880M
YoY Change -4.65% 25.76%
% of Gross Profit 6397.62% 423.53%
Research & Development $2.255M $1.870M
YoY Change -29.07% -9.66%
% of Gross Profit 5369.05% 275.0%
Depreciation & Amortization $80.00K $80.00K
YoY Change 14.29% -11.11%
% of Gross Profit 190.48% 11.76%
Operating Expenses $5.002M $4.750M
YoY Change -17.43% 8.94%
Operating Profit -$3.927M -$4.070M
YoY Change -8.59% 149.69%
Interest Expense $331.0K -$650.0K
YoY Change -56.79% 85.71%
% of Operating Profit
Other Income/Expense, Net $90.00K $900.0K
YoY Change -68.42% 4400.0%
Pretax Income -$4.170M -$4.050M
YoY Change -11.58% 106.63%
Income Tax $10.00K -$200.0K
% Of Pretax Income
Net Earnings -$4.180M -$3.860M
YoY Change -9.5% 93.97%
Net Earnings / Revenue -4098.04% -285.93%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.883M -$1.731M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.89M $50.24M
YoY Change -27.43% 203.2%
Cash & Equivalents $10.47M $23.97M
Short-Term Investments $43.41M $26.27M
Other Short-Term Assets $1.190M $690.0K
YoY Change 77.61% 146.43%
Inventory $360.0K $294.0K
Prepaid Expenses
Receivables $240.0K $706.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $55.68M $52.02M
YoY Change -27.35% 178.24%
LONG-TERM ASSETS
Property, Plant & Equipment $580.0K $585.0K
YoY Change -2.85% -19.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.480M $19.75M
YoY Change 596.0% 3850.0%
Other Assets $1.850M $25.00K
YoY Change 1713.73% -99.11%
Total Long-Term Assets $5.910M $22.23M
YoY Change 77.42% 258.81%
TOTAL ASSETS
Total Short-Term Assets $55.68M $52.02M
Total Long-Term Assets $5.910M $22.23M
Total Assets $61.59M $74.24M
YoY Change -22.99% 198.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.00K $440.0K
YoY Change 0.0% 46.67%
Accrued Expenses $2.000M
YoY Change -32.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $3.830M $3.450M
YoY Change -64.85% -69.39%
LONG-TERM LIABILITIES
Long-Term Debt $25.08M $24.93M
YoY Change 28.85% 181.09%
Other Long-Term Liabilities $5.170M $3.000M
YoY Change 72.33% 0.0%
Total Long-Term Liabilities $25.08M $27.93M
YoY Change 11.64% 4.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.830M $3.450M
Total Long-Term Liabilities $25.08M $27.93M
Total Liabilities $34.08M $34.02M
YoY Change -5.7% 27.05%
SHAREHOLDERS EQUITY
Retained Earnings -$131.9M
YoY Change 15.76%
Common Stock $172.3M
YoY Change 489.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.51M $40.23M
YoY Change
Total Liabilities & Shareholders Equity $61.59M $74.24M
YoY Change -22.99% 198.29%

Cashflow Statement

Concept 2016 Q3 2015 Q4
OPERATING ACTIVITIES
Net Income -$4.180M -$3.860M
YoY Change -9.5% 93.97%
Depreciation, Depletion And Amortization $80.00K $80.00K
YoY Change 14.29% -11.11%
Cash From Operating Activities -$3.930M -$3.950M
YoY Change -14.19% 48.5%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$70.00K
YoY Change -66.67% -36.36%
Acquisitions
YoY Change
Other Investing Activities -$13.09M -$34.92M
YoY Change 15.94%
Cash From Investing Activities -$13.11M -$34.99M
YoY Change 15.51% 31709.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 150.0K -60.00K
YoY Change -113.51% -96.74%
NET CHANGE
Cash From Operating Activities -3.930M -3.950M
Cash From Investing Activities -13.11M -34.99M
Cash From Financing Activities 150.0K -60.00K
Net Change In Cash -16.89M -39.00M
YoY Change -0.88% 745.99%
FREE CASH FLOW
Cash From Operating Activities -$3.930M -$3.950M
Capital Expenditures -$20.00K -$70.00K
Free Cash Flow -$3.910M -$3.880M
YoY Change -13.5% 52.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131926000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-115000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23973000
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
26270000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
706000
CY2015Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
82000
CY2015Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1867000
CY2015Q4 us-gaap Long Term Investments
LongTermInvestments
19748000
CY2015Q4 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
24930000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
383000
us-gaap Contracts Revenue
ContractsRevenue
2912000
us-gaap Sales Revenue Net
SalesRevenueNet
4068000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3450000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2637000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3000000
CY2015Q4 us-gaap Liabilities
Liabilities
34017000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
172222000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
222000
us-gaap Net Income Loss
NetIncomeLoss
-14099000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
223000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7097000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8241000
us-gaap Operating Expenses
OperatingExpenses
15561000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11493000
us-gaap Interest Expense
InterestExpense
2008000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-376000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13877000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-277000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12778000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
11290000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
68226000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
20000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
290000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.016
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
68928000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
168000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
8000000
rkda Payments For Notes Payable And Convertible Promissory Notes
PaymentsForNotesPayableAndConvertiblePromissoryNotes
3122000
us-gaap Interest Paid
InterestPaid
1411000
us-gaap Income Taxes Paid
IncomeTaxesPaid
149000
rkda Accretion Of Redeemable Convertible Preferred Stock
AccretionOfRedeemableConvertiblePreferredStock
2574000
rkda Deferred Stock Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
155000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1000
rkda Reclassification Of Deferred Initial Public Offering Costs To Equity
ReclassificationOfDeferredInitialPublicOfferingCostsToEquity
5026000
rkda Issuance Of Warrants And Derivatives In Connection With Notes Payable Issuance
IssuanceOfWarrantsAndDerivativesInConnectionWithNotesPayableIssuance
437000
rkda Stock Option Exercise Cost Included In Accounts Receivable
StockOptionExerciseCostIncludedInAccountsReceivable
6000
rkda Stock Option Exercise Cost Included In Accounts Receivable
StockOptionExerciseCostIncludedInAccountsReceivable
19000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
85455000
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Arizona
rkda Entity Incorporation Year Of Incorporation
EntityIncorporationYearOfIncorporation
2002
rkda Entity Reincorporation State Country Name
EntityReincorporationStateCountryName
Delaware
rkda Entity Reincorporation Date Of Reincorporation
EntityReincorporationDateOfReincorporation
2015-03
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-four
us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
At the closing of the IPO, all of the outstanding shares of convertible preferred stock and redeemable convertible preferred stock were automatically converted into 32,972,793 shares of common stock.
CY2015Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
32972793
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q3 rkda Inventory Raw Materials Current And Non Current
InventoryRawMaterialsCurrentAndNonCurrent
789000
CY2015Q4 rkda Inventory Raw Materials Current And Non Current
InventoryRawMaterialsCurrentAndNonCurrent
665000
CY2016Q3 rkda Inventory Finished Goods Current And Non Current
InventoryFinishedGoodsCurrentAndNonCurrent
1403000
CY2015Q4 rkda Inventory Finished Goods Current And Non Current
InventoryFinishedGoodsCurrentAndNonCurrent
1496000
CY2016Q3 rkda Inventory Current And Non Current Net
InventoryCurrentAndNonCurrentNet
2192000
CY2015Q4 rkda Inventory Current And Non Current Net
InventoryCurrentAndNonCurrentNet
2161000
CY2016Q3 rkda Inventory Reserves For Excess And Slow Moving Inventory
InventoryReservesForExcessAndSlowMovingInventory
2300000
CY2015Q4 rkda Inventory Reserves For Excess And Slow Moving Inventory
InventoryReservesForExcessAndSlowMovingInventory
2300000
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
56965000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
56958000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
67930000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
116000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
67815000
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
rkda Maturity Of Long Term Investments
MaturityOfLongTermInvestments
2017
CY2016Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
56958000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
67815000
us-gaap Variable Interest Entity Terms Of Arrangements
VariableInterestEntityTermsOfArrangements
Both the Company and Bioceres incur expenses in support of specific agreed activities, as defined by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. An agreement executed in conjunction with the formation of Verdeca specified that if Bioceres determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0 million in the aggregate over a four-year period.
rkda Contributed Services Period
ContributedServicesPeriod
P4Y
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
2000000
CY2014Q3 rkda Common Stock Shares Surrendered
CommonStockSharesSurrendered
1832
CY2015 rkda Research Agreement Settled
ResearchAgreementSettled
205000
CY2015Q4 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
632
CY2015Q4 us-gaap Fair Value Hedges At Fair Value Net
FairValueHedgesAtFairValueNet
500000
CY2015Q4 us-gaap Cost Method Investments
CostMethodInvestments
0
CY2016Q3 us-gaap Variable Interest Entity Activity Between Vie And Entity Expense
VariableInterestEntityActivityBetweenVIEAndEntityExpense
98000
CY2015Q3 us-gaap Variable Interest Entity Activity Between Vie And Entity Expense
VariableInterestEntityActivityBetweenVIEAndEntityExpense
875000
us-gaap Variable Interest Entity Activity Between Vie And Entity Expense
VariableInterestEntityActivityBetweenVIEAndEntityExpense
221000
us-gaap Variable Interest Entity Activity Between Vie And Entity Expense
VariableInterestEntityActivityBetweenVIEAndEntityExpense
1200000
CY2016Q3 us-gaap Long Term Debt
LongTermDebt
25077000
CY2015Q4 us-gaap Long Term Debt
LongTermDebt
24930000
CY2016Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25077000
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
24930000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
197000
rkda Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3427509
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1751485
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
219730
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
266641
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4692623
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4692623
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2801217
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.76
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.27
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.36
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.61
rkda Class Of Warrant Or Right Exercisable Term
ClassOfWarrantOrRightExercisableTerm
P5Y
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.35
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.35
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.63
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3707000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1173000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1173000
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1053000
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.44
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
CY2015Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.021
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6029517
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5401892

Files In Submission

Name View Source Status
0001564590-16-028976-index-headers.html Edgar Link pending
0001564590-16-028976-index.html Edgar Link pending
0001564590-16-028976.txt Edgar Link pending
0001564590-16-028976-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201611101741438731230.jpg Edgar Link pending
g201611101741440091231.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rkda-10q_20160930.htm Edgar Link pending
rkda-20160930.xml Edgar Link completed
rkda-20160930.xsd Edgar Link pending
rkda-20160930_cal.xml Edgar Link unprocessable
rkda-20160930_def.xml Edgar Link unprocessable
rkda-20160930_lab.xml Edgar Link unprocessable
rkda-20160930_pre.xml Edgar Link unprocessable
rkda-ex1015_7.htm Edgar Link pending
rkda-ex311_10.htm Edgar Link pending
rkda-ex312_9.htm Edgar Link pending
rkda-ex321_8.htm Edgar Link pending
rkda-ex322_6.htm Edgar Link pending
Show.js Edgar Link pending